NeuroSense Therapeutics Reports New ALS Study Data
Ticker: NRSNW · Form: 6-K · Filed: Feb 19, 2025 · CIK: 1875091
Sentiment: neutral
Topics: clinical-trial-data, biotech, als
TL;DR
NeuroSense dropped new ALS trial data, showing more results from their PARADIGM study.
AI Summary
NeuroSense Therapeutics Ltd. announced additional findings from its 18-month Phase 2b PARADIGM study of PrimeC for Amyotrophic Lateral Sclerosis (ALS). The report includes new data from the pre-defined Per Protocol population, supplementing previously reported ALSFRS-R and overall survival data from the Intent to Treat population.
Why It Matters
This filing provides updated clinical trial results for PrimeC, a potential treatment for ALS, which could impact the company's future development and investor outlook.
Risk Assessment
Risk Level: medium — The company is reporting clinical trial data, which inherently carries risks related to efficacy and future regulatory approval.
Key Numbers
- 18-month — Study Duration (Duration of the PARADIGM Phase 2b study)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- PrimeC (drug) — Investigational drug for ALS
- Amyotrophic Lateral Sclerosis (ALS) (disease) — Condition being studied
- PARADIGM (study) — Name of the Phase 2b clinical trial
FAQ
What specific new data from the Per Protocol population was presented in the filing?
The filing states that additional results from the 18-month PARADIGM study read-out are presented, including new data from the pre-defined Per Protocol population, but the specific details of this data are not included in the provided text.
What is the primary indication being studied for PrimeC?
PrimeC is being evaluated for Amyotrophic Lateral Sclerosis (ALS).
What is the name of the clinical trial mentioned?
The clinical trial is named the Phase 2b PARADIGM study.
What previous data from the PARADIGM study has NeuroSense Therapeutics Ltd. reported?
The company previously reported ALSFRS-R and overall survival data from the Intent to Treat population.
What form is this SEC filing?
This is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 19, 2025 regarding NeuroSense Therapeutics Ltd. (NRSNW).